Search - tctmd.com

Displaying 101 - 120 of 196

Sort: Relevancy | Date

Presentation TCT 2016

NeoVas PLLA-Based Sirolimus-Eluting Scaffold: Early Results and Phase III Completion

Presenter: Ron Waksman, Robert-Jan van Geuns, Guosheng Fu

October 31, 2016

Presentation TCT 2016

FIRESORB PLLA-Based Sirolimus-Eluting Scaffold: 6-Month FUTURE-I Results

Presenter: Ron Waksman, Robert-Jan van Geuns, Bo Xu

October 31, 2016

Presentation TCT 2016

TCT 261: Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-Eluting and Birolimus-Eluting Stents with Biodegradable Polymer. From the SORT OUT VII Trial

Presenter: Kevin J. Beatt, Frederick Feit

October 31, 2016

Presentation TCT 2016

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

Presenter: Michael J. Cowley, Franz-Josef Neumann, Shunsuke Kubo

October 31, 2016

Presentation TCT 2016

TCT 69: A Randomized Comparison of the Second Generation Biodegradable Polymer Sirolimus-Eluting Stent (EXCEL-II) and the First Generation EXCEL-I Stent in Patients With De Novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial

Presenter: Giuseppe De Luca, Christoph A. Kaiser, Li Zhi

October 31, 2016

Presentation TCT 2016

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu

October 31, 2016

Presentation TCT 2016

TCT 31: Impact of Strut Thickness on Short-term Healing Response After Bioresorbable Scaffold Implantation: Serial OCT Evaluation of Novel Thin Strut Sirolimus-Eluting BRS vs Thick Strut Everolimus-Eluting BRS in Porcine Coronary Arteries

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Pawel Gasior

October 31, 2016

Presentation TCT 2016

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo

October 31, 2016

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Presentation TCT 2016

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Alexandre Abizaid

October 31, 2016

Presentation TCT 2016

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Jo Simonsen

October 31, 2016

Presentation TCT 2016

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Jo Simonsen

October 31, 2016

Presentation TCT 2016

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Stephen G. Worthley

October 31, 2016

Presentation TCT 2016

TCT 317: Ten-Year Impact of Stent Fracture and Peri-Stent Contrast staining After Sirolimus-Eluting Stent Implantation on Target Lesion Revascularization

Presenter: Nicolas Foin, Giampaolo Niccoli

October 31, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Thomas Pilgrim

October 30, 2016

Presentation TCT 2015

PANDA III: A Prospective Randomized Trial of Two Sirolimus-Eluting Bioresorbable-Polymer-Based Metallic Stents With Varying Elution and Absorption Kinetics

Presenter: Cindy L. Grines, Bo Xu

October 14, 2015

Presentation TCT 2015

Sirolimus-Eluting Angioplasty Balloon for In-Stent Restenosis (SABRE Trial): Six-Month Clinical and Angiographic Results

Presenter: Andrea Abizaid, Daniel Burkhoff, Juan F. Granada

October 14, 2015

Presentation TCT 2015

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

Presenter: Bo Xu

October 14, 2015

Presentation TCT 2015

TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Yaling Han

October 13, 2015

Presentation TCT 2015

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Bo Xu

October 13, 2015

Advertisement

NeoVas PLLA-Based Sirolimus-Eluting Scaffold: Early Results and Phase III Completion

FIRESORB PLLA-Based Sirolimus-Eluting Scaffold: 6-Month FUTURE-I Results

TCT 261: Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-Eluting and Birolimus-Eluting Stents with Biodegradable Polymer. From the SORT OUT VII Trial

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

TCT 69: A Randomized Comparison of the Second Generation Biodegradable Polymer Sirolimus-Eluting Stent (EXCEL-II) and the First Generation EXCEL-I Stent in Patients With De Novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 31: Impact of Strut Thickness on Short-term Healing Response After Bioresorbable Scaffold Implantation: Serial OCT Evaluation of Novel Thin Strut Sirolimus-Eluting BRS vs Thick Strut Everolimus-Eluting BRS in Porcine Coronary Arteries

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

TCT 317: Ten-Year Impact of Stent Fracture and Peri-Stent Contrast staining After Sirolimus-Eluting Stent Implantation on Target Lesion Revascularization

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

PANDA III: A Prospective Randomized Trial of Two Sirolimus-Eluting Bioresorbable-Polymer-Based Metallic Stents With Varying Elution and Absorption Kinetics

Sirolimus-Eluting Angioplasty Balloon for In-Stent Restenosis (SABRE Trial): Six-Month Clinical and Angiographic Results

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content